AUSTIN, Texas, Sept. 12, 2024 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and a company of Centene Corporation (NYSE: CNC), announced today it invested $43.3 million in extra Medicaid and Children's Health Insurance Program (CHIP) benefits from 2019 through 2023. Known as Value-added Services, the extra benefits help provide additional support for low-income families and individuals across all 254 Texas counties.
"For 25 years, Superior HealthPlan has looked for ways to support our members by providing them with extra benefits not covered by Medicaid or CHIP," said President and CEO of Superior HealthPlan, Mark Sanders. "This investment is yet another example of how we do more for our members to improve the health of each individual we serve."
Value-added Services* from Superior include a variety of extra benefits that are designed to promote healthy behaviors. *Restrictions and limitations may apply.
These extra benefits include:
Over a five-year period, nearly half of spending – or $15.5 million – for Value-added Services was on vision care. Superior spent another $12 million on over-the-counter items, $11 million on dental care, and $2.5 million on sports physicals.
"Medicaid and CHIP coverage is a lifeline for millions of Texans each year," said Superior's Senior Vice President of Population Health & Clinical Operations, Dr. Susan Mills. "We're proud to add on to those benefits with these Value-added Services because we know they make a real difference in people's lives."
Value-added Services are updated each year on September 1. To see a full list, visit SuperiorHealthPlan.com/VAS.
About Superior HealthPlan
Founded in 1999, Superior HealthPlan is a managed care company that delivers quality healthcare throughout Texas. Committed to transforming the health of the community, one person at a time, Superior supports active local involvement in all 254 Texas counties with more than 3,200 employees throughout the state. Superior is a company of Centene Corporation, a leading healthcare enterprise that is committed to helping people live healthier lives. For more information visit www.SuperiorHealthPlan.com.
Last Trade: | US$75.63 |
Daily Change: | -0.69 -0.90 |
Daily Volume: | 3,098,724 |
Market Cap: | US$39.780B |
September 11, 2024 August 29, 2024 July 26, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB